Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05597241 · ClinicalTrials.gov registry record · Phase 1
Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers
A Phase 1 study of Major Depressive Disorder, sponsored by Syndeio Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT05597241 is a Phase 1 study of Major Depressive Disorder that has completed, run by Syndeio Biosciences. The registered enrollment target is 40 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05597241, a Phase 1 study of Major Depressive Disorder, has completed, sponsored by Syndeio Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To evaluate the safety, tolerability, pharmacokinetics and EEG pharmacodynamics of single and multiple ascending doses of apimostinel in normal human volunteers
Conditions Studied
Interventions
- DRUG Placebo
- DRUG apimostinel
Study Locations (1)
Arkansas
- Woodland Research Northwest - Rogers
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2022-10-15 |
| Est. Completion | 2023-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05597241
The ClinicalTrials.gov registry entry for NCT05597241 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (89% lower). The listed sponsor is Syndeio Biosciences, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05597241 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT05597241 about?
NCT05597241 is a clinical study titled "Multiple Ascending Dose and Electroencephalography Trial of GATE-202 in Healthy Volunteers". To evaluate the safety, tolerability, pharmacokinetics and EEG pharmacodynamics of single and multiple ascending doses of apimostinel in normal human volunteers
What is the current status of trial NCT05597241?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2022-10-15. Estimated completion is 2023-04-04.
What conditions does trial NCT05597241 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT05597241?
The interventions under investigation include: Placebo (DRUG), apimostinel (DRUG).
Who is sponsoring clinical trial NCT05597241?
This trial is sponsored by Syndeio Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05597241 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neural Response to Inflammatory Challenge in Major Depressive Disorder
RECRUITING · Phase 1
-
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
RECRUITING · Phase 1
-
Mechanism of Action Underlying Ketamine's Antidepressant Effects: The AMPA Throughput Theory in Patients With Treatment-Resistant Major Depression
RECRUITING · Phase 1
-
A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression
RECRUITING · Phase 1
-
Antiviral Treatment OF Cytomegalovirus IN Depression
RECRUITING · Phase 1
-
Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.